AMD 2016: A Review of Treatment Guidelines and the Role of Appropriate Therapy
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Overview
CONTENT SOURCE This continuing medical education (CME) activity captures content from a roundtable meeting held in February of 2016 in Vail, Colorado. TARGET AUDIENCE This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.Jointly provided by Evolve Medical Education LLC, New Retina MD, and Retina Today. Supported through an unrestricted educational grant by Regeneron Pharmaceuticals. Learning Objectives
Upon completion of this activity, the participant should be able to:
- Assess the most recent monotherapy and combination therapy clinical study evidence using available anti-VEGF therapies for common retinal diseases, including AMD.
- Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations.
- Develop plans to initiate treatment for conditions such as AMD using anti-VEGF agents as well as better understand when to change therapeutic strategies.
Accreditation
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, New Retina MD, and Retina Today. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT Evolve Medical Education LLC (Evolve) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Brandon G. Busbee, MD Tennessee Retina Nashville, Tennessee
Justis P. Ehlers, MD Cole Eye Institute Cleveland, Ohio
Allen C. Ho, MD Retina Service Wills Eye Institute Philadelphia, Pennsylvania
Darius M. Moshfeghi, MD Stanford University Medical Center Stanford, California
John D. Pitcher, III, MD Eye Associates of New Mexico Albuquerque, New Mexico
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Brandon G. Busbee, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board/Speaker’s Bureau: Aerpio Therapeutics; Genentech, and Valeant Pharmaceuticals International. Grant/Research Support: Aerpio Therapeutics; Genentech; Ohr Pharmaceutical; Opthotech; and Regeneron Pharmaceuticals. Stock/Shareholder: Akorn. Other Financial/Material Support: Akorn.
Justis P. Ehlers, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Bioptigen; Carl Zeiss Meditec; Leica Microsystems; Santen Pharmaceutical Co., Ltd.; ThromboGenics NV. Grant/ Research Support: Genentech; Regeneron Pharmaceuticals, and ThromboGenics NV.
Allen C. Ho, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Advisory Board/Consultant/Speaker’s Bureau: Aerpio Therapeutics; Alcon; Allergan; Beaver-Visitic International; DigiSight Technologies; Endo Optiks; Genentech; Janssen Pharmaceuticals/ Johnson & Johnson; ONL Therapeutics, LLC; Ophthotech; Physician Recommended Nutriceuticals; Regeneron Pharmaceuticals; Regenix; and Second Sight. Grant/Research Support: Alcon; Allergan; Genentech; Janssen Pharmaceuticals/Johnson & Johnson; NEI/NIH; Ophthotech; Physician Recommended Nutriceuticals; Regeneron Pharmaceuticals; and Second Sight.
Darius M. Moshfeghi, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan; and Genentech. Travel: Clarity Medical Systems. Founder/ IP/Equity: InSitu Therapeutics. Steering Committee/Consultant: Iconic
Therapeutics. Consultant/equity: Krypton Vision and Visunex. Founder/Equity: Promisight and Versl.
John D. Pitcher III, MD, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of: Consultant/Advisory Board/Speaker’s Bureau: Allergan.
Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Emily Feinman, administrator, BMC; Michelle Dalton, medical writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, New Retina MD, Retina Today, or Regeneron Pharmaceuticals.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
Christina Y. Weng, MD, MBA, FASRS
Katherine E. Talcott, MD
Katherine E. Talcott, MD
Christina Y. Weng, MD, MBA, FASRS
Roger A. Goldberg, MD, MBA
